Floatz logo

e6 tcr

Penile Cancer

National Cancer Institute (NCI)Cell therapyPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
81/ 100

Competitive context

17 Active assets in the Penile Cancer cohort.

View all 28

Same molecule, other indications

e6 tcr is also rated in:

oropharyngeal carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
vaginal cancerDormant
CCC
Indicative ·
50 / 100
View asset →
anal carcinomaDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →